NNC 45-0095

NNC 45-0095 is a chemical compound that belongs to the class of calcium channel blockers. It was developed by the Novo Nordisk company, hence the prefix "NNC" in its name. This compound is known for its selective inhibitory effect on the T-type calcium channel, which plays a crucial role in various physiological processes.

History

NNC 45-0095 was first synthesized and studied by the Danish pharmaceutical company Novo Nordisk. The company is known for its extensive research in the field of pharmacology and drug discovery, with a particular focus on diabetes and other metabolic disorders.

Pharmacology

NNC 45-0095 is a potent and selective inhibitor of the T-type calcium channel. Calcium channels are protein complexes that facilitate the movement of calcium ions across cell membranes. The T-type calcium channel is one of the several types of calcium channels found in the body. It is characterized by its transient opening and closing, hence the name "T-type" (transient type).

The inhibition of T-type calcium channels by NNC 45-0095 has been found to have potential therapeutic applications. For instance, it has been suggested that this compound could be used in the treatment of certain types of epilepsy, as well as in the management of pain and hypertension.

Clinical significance

The clinical significance of NNC 45-0095 lies in its potential therapeutic applications. Its ability to selectively inhibit T-type calcium channels makes it a promising candidate for the development of new drugs for the treatment of various disorders, including epilepsy, pain, and hypertension.

However, as of now, NNC 45-0095 is primarily used in research settings. Further studies are needed to fully understand its pharmacological properties and potential therapeutic benefits.

See also

• Calcium channel blocker
• T-type calcium channel
• Novo Nordisk